Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyPresbyterian NIPT Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedPresbyterian Health PlanPolicy 20.15

    Genetic Testing for Non-Invasive Prenatal Testing (NIPT)

    Customize your policy alerts

    Sign up for Presbyterian Health Plan Policy 20.15 alerts

    Get alerted when Policy 20.15 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage, prior authorization, medical necessity, limitations, and exclusions for cell-free fetal DNA testing during pregnancy, including aneuploidy screening and fetal RhD genotyping. Coverage depends on the member’s specific benefit plan and Schedule of Benefits.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyGenetic Testing for Non-Invasive Prenatal Testing (NIPT)
    Policy CodePolicy 20.15
    Change TypeModified
    Effective DateN/A
    Last ReviewMar 25, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for applicable NIPT services, except codes 81420, 81507, and 0327U.
    SourceLink
    POLICY UPDATE CHANGES

    Coverage was expanded to include viable twin pregnancies greater than 10 weeks gestation in addition to singleton pregnancies.

    The policy added explicit experimental or investigational examples including twin zygosity, rare autosomal trisomies, microdeletions, single-gene disorders, miscarriage-cause testing, nonmedical traits, and the Luna Prenatal Test.

    Prior authorization is currently not required for codes 81420, 81507, and 0327U, while prior authorization remains required for other applicable services under the policy.

    The policy established a limit of no more than two NIPT tests in a rolling 12-month period.

    Code 0536U was added to the non-covered code section and is configured as investigational and experimental.

    Codes 0252U and 0254U were removed from this policy and moved to MPM 7.1 because they are not related to non-invasive prenatal testing.

    Code 0060U was removed from the LBM policy and management was moved back to this policy, with the code configured as investigational and experimental.

    The 2026 annual review reported that the coverage criteria and exclusion section remained unchanged while codes were evaluated and updated.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥10 weeksMinimum gestational age for covered aneuploidy NIPT
    2Maximum NIPT tests in a rolling 12-month period
    3Core aneuploidies screened by covered NIPT
    81420, 81507, 0327UCodes exempt from prior authorization
    0494U, 81403Fetal RhD genotyping codes requiring prior authorization
    ExperimentalNIPT for higher-order multiples and other excluded indications

    Coverage Criteria

    NIPT Aneuploidy Screening

    Covered when ALL of the following criteria are met:

    ALL of the following

    • The individual is pregnant, regardless of maternal age or risk of chromosomal abnormality, with a singleton or twin pregnancy greater than 10 weeks gestation.
    • The NIPT is ordered by a healthcare professional who regularly manages pregnancy.
    • There is no documentation that a chromosomal abnormality screening test has been performed during the current pregnancy, including sequential serum Part 1 screening (CPT 81508), sequential serum Part 2 screening (CPT 81511), quadruple screening (CPT 81511), penta screening (CPT 81512), or serum integrated or contingent screening.
    • The individual has the capacity to make fully informed decisions and provide consent for treatment.
    • The individual receives genetic counseling from a certified genetic counselor or qualified healthcare professional.
    • When screening for aneuploidy, only one screening approach is used; analyte screening and cell-free DNA screening are not sent concurrently.

    Fetal RhD Genotyping

    Measurement of cell-free DNA for fetal genotyping for RhD is medically necessary when ALL of the following are met:

    ALL of the following

    • The test is cell-free DNA testing for fetal RhD genotyping.
    • All medical-necessity criteria in MCG A-0724, Noninvasive Prenatal Testing (Cell-Free Fetal DNA), are met.
    • The service is billed with an applicable covered RhD fetal-genotyping code, including 0494U or 81403, subject to applicable prior-authorization requirements.

    NIPT Frequency Limitation

    NIPT is subject to the following utilization requirements:

    ALL of the following

    • No more than two NIPT tests are performed in a rolling 12-month period.<= 2 tests per rolling 12 months
    • If NIPT is repeated, documentation establishes that the repeat test is for a new pregnancy.

    Medically Necessary Sequencing-Based NIPT

    Sequencing-based NIPT is medically necessary when ALL of the following criteria are met:

    ALL of the following

    • The individual is pregnant with a viable singleton or twin gestation.
    • The pregnancy is at least 10 weeks gestation.>= 10 weeks gestation
    • The test is used to screen for fetal trisomy 13, trisomy 18, and trisomy 21.
    • The test is ordered by a healthcare professional who regularly manages pregnancy.
    • The individual has the capacity to make fully informed decisions and provide consent for treatment and receives appropriate genetic counseling.

    Investigational and Experimental Testing

    The following indications and test types are considered experimental, investigational, unproven, or non-covered:

    Experimental, investigational, or non-covered testing

    • NIPT for higher-order multiple gestations, including triplets and higher.
    • Sequencing-based NIPT for twin zygosity, including code 0060U.
    • Screening for trisomy 7, 9, 16, 22, or other rare autosomal trisomies.
    • Screening for fetal chromosomal copy-number variants or microdeletions, including CPT 81422.
    • Screening for single-gene disorders, including UNITY Fetal Risk (0489U).

    Higher-order multiple gestations, including triplets and higher, are considered experimental or investigational.

    NIPT for higher-order multiple gestations is not covered under this policy.

    Sequencing-based NIPT is considered experimental or investigational for twin zygosity; screening for trisomy 7, 9, 16, 22, or other rare autosomal trisomies; screening for microdeletions; screening for single-gene disorders; testing used to determine the genetic cause of miscarriage; screening for nonmedical traits; and the Luna Prenatal Test.

    Examples of non-covered or investigational services include twin zygosity testing (0060U), Luna Prenatal Test (0341U), fetal chromosomal microdeletion testing (81422), and single-gene testing such as UNITY Fetal Risk (0489U).

    Cell-free DNA testing for non-RhD red blood cell antigens, including code 0488U, is considered experimental, investigational, or unproven because of limited supporting data.

    Fetal RhD testing with code 0536U is considered experimental and investigational. The assay evaluates a limited region of the RHD gene, while current clinical best practices recommend evaluating multiple RHD gene regions to reduce false-negative results from D-variant alleles.

    Fetal RhD genotyping that meets MCG A-0724 criteria may be medically necessary when performed with an applicable covered service, including 0494U or 81403.

    Higher-order multiple gestations, including triplets and higher, are experimental under this policy.

    The following are excluded or considered experimental and investigational: twin zygosity; microdeletions; rare autosomal trisomies, including trisomy 7, 9, 16, and 22; single-gene disorders; testing to determine the genetic cause of miscarriage; screening for nonmedical traits; and the Luna Prenatal Test.

    ACOG does not support or recommend cell-free DNA testing for evaluation of single-gene disorders. Accordingly, the UNITY Fetal Risk assay (0489U), including its reflex evaluation of single-gene disorders after a positive maternal carrier screen, is considered experimental and investigational.

    Only one aneuploidy screening approach should be used during a pregnancy. Analyte screening and cell-free DNA screening should not be sent concurrently because this strategy is not cost-effective and simultaneous, potentially discordant results may cause more distress than a positive analyte screen followed by reassuring cell-free DNA screening.

    Cell-free DNA screening as follow-up to a positive serum analyte screening result may be reviewed on a case-by-case basis for an individual seeking to avoid diagnostic testing such as amniocentesis or chorionic villus sampling.

    When aneuploidy screening with CPT 81420 or 81507 has been performed, additional chromosomal-abnormality screening tests for the same pregnancy are not medically necessary and may not be covered. Only one screening approach is considered medically necessary.

    This restriction applies to maternal serum screening codes 81508, 81509, 81510, 81511, and 81512 when aneuploidy screening with CPT 81420 or 81507 has already been performed.

    Coding and Service Codes

    Covered aneuploidy NIPT codesCPTCovered
    81420Fetal chromosomal aneuploidy genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, including chromosomes 13, 18, and 21.
    81507Fetal aneuploidy DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy.
    0327UFetal aneuploidy DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for trisomies 13, 18, and 21, including sex reporting if performed.
    Fetal RhD genotyping codesCPTCovered
    81403RHD mutation scanning or duplication/deletion variant analysis performed on cell-free fetal DNA in maternal blood for fetal RhD genotyping.
    0494UFetal RhD gene analysis by next-generation sequencing of circulating cell-free DNA in blood from pregnant individuals known to be RhD negative, reported as positive or negative; includes Rh Test, Natera.
    Non-covered or experimental NIPT codesCPTNot Covered
    0341UFetal aneuploidy DNA sequencing comparative analysis from fetal DNA from products of conception, reported as normal, monosomy, trisomy, partial deletion/duplication, mosaicism, or segmental aneuploidy; includes Single Cell Prenatal Diagnosis Test, Luna Genetics.
    81422Fetal chromosomal microdeletion genomic sequence analysis using circulating cell-free fetal DNA in maternal blood.
    0488UFetal antigen noninvasive prenatal test using cell-free DNA sequence analysis to detect fetal Rh, C, c, D, E, Duffy (Fya), or Kell antigens in alloimmunized pregnancies; includes UNITY Fetal Antigen NIPT.
    0489USingle-gene noninvasive prenatal test using cell-free DNA sequence analysis and mutation-dosage analysis to identify fetal inheritance risk for conditions such as cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies, and alpha thalassemia; includes UNITY Fetal Risk Screen.
    0536UFetal RhD PCR analysis of exon 4 of the RHD gene and GAPDH control gene from whole blood in pregnant individuals at 10 or more weeks gestation known to be RhD negative; includes Prenatal Detect RhD.
    0060UTwin zygosity genomic-targeted sequence analysis of chromosome 2 using circulating cell-free fetal DNA in maternal blood.
    Other chromosomal abnormality screening codes potentially not covered after NIPTCPTNot Covered
    81508Fetal congenital abnormalities biochemical assays of two proteins, PAPP-A and hCG, using maternal serum and reported as a risk score.
    81509Fetal congenital abnormalities biochemical assays of three proteins, PAPP-A, hCG, and DIA, using maternal serum and reported as a risk score.
    81510Fetal congenital abnormalities biochemical assays of three analytes, AFP, uE3, and hCG, using maternal serum and reported as a risk score.
    81511Fetal congenital abnormalities biochemical assays of four analytes, AFP, uE3, hCG, and DIA, using maternal serum and reported as a risk score.
    81512Fetal congenital abnormalities biochemical assays of five analytes, AFP, uE3, total hCG, hyperglycosylated hCG, and DIA, using maternal serum and reported as a risk score.
    Covered TableCPTCovered
    81420Code listed under the covered table; gold-carded and exempted from prior authorization for all lines of business effective 10/01/2022.
    81507Sequencing-based non-invasive prenatal testing to screen for fetal trisomy 13, 18, and 21.
    0327USequencing-based non-invasive prenatal testing to screen for fetal trisomy 13, 18, and 21.
    81403Molecular code listed under the covered table.
    0494UcfDNA-based testing for Rh-D alone.
    Non-covered codesCPTNot Covered
    0060UTwins Zygosity test; configured as investigational and experimental after management returned from the LBM policy.
    0341ULuna test; considered investigational and experimental.
    81422Screening for microdeletions; considered investigational and experimental.
    0488UUNITY Fetal Antigen; testing of one or more Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigens; considered investigational and experimental.
    0489UUNITY Fetal Risk; includes a cfDNA-based reflex component for single-gene disorders; considered investigational and experimental.
    0536URhD assay measuring circulating tumor DNA limited to a single exon of the RHD gene for fetal RhD genotyping; configured as investigational and experimental.
    Maternal serum screening codesCPTCovered
    81508Maternal serum screening test.
    81509Maternal serum screening test.
    81510Maternal serum screening test.
    81511Maternal serum screening test.
    81512Maternal serum screening test.
    Codes moved to MPM 7.1CPT
    0252UFetal aneuploidy code removed from this policy and moved to MPM 7.1 because it is not related to non-invasive prenatal testing.
    0254UFetal aneuploidy code removed from this policy and moved to MPM 7.1 because it is not related to non-invasive prenatal testing.
    Gestational Age
    ThresholdGreater than 10 weeks of gestation
    Eligible pregnancySingleton or twin pregnancy
    Applicable screeningAneuploidy NIPT screening
    NIPT Utilization Limit
    Utilization limitNo more than two NIPT tests
    Measurement period

    Provider Actions and Authorization

    Prior Authorization

    General NIPT Prior Authorization

    Prior authorization is required for NIPT services except codes 81420, 81507, and 0327U. Use the Prior Authorization/Benefit Certification Guide to determine when prior authorization or benefit certification is required.

    • Exceptions to the general NIPT authorization requirement: 81420, 81507, and 0327U.
    • Prior Authorization/Benefit Certification Guide: https://ds.phs.org/preslogin/index.jsp
    Prior Authorization

    RhD Genotyping Authorization

    Prior authorization is required for fetal RhD genotyping codes 0494U and 81403 for Medicare, Medicaid, and Commercial members. PHP considers cfDNA fetal RhD genotyping medically necessary when all criteria in MCG A-0724, Noninvasive Prenatal Testing (Cell-Free Fetal DNA), are met.

    • Affected codes: 0494U and 81403.
    • Applies to Medicare, Medicaid, and Commercial members.
    • Coverage follows the applicable MCG A-0724 criteria.

    Policy Background

    NIPT uses cell-free fetal DNA from maternal blood to screen for fetal aneuploidy, primarily trisomies 13, 18, and 21, beginning as early as 10 weeks of pregnancy. NIPT is a screening test rather than a diagnostic test and cannot diagnose or exclude every chromosomal disorder. It may reduce the need for invasive procedures such as amniocentesis or chorionic villus sampling, but may also produce no-call or false-positive results.

    Definitions

    Definitions
    TermAneuploidy
    DefinitionAny deviation from an exact multiple of the haploid number of chromosomes
    Chromosomal basisThe haploid number of chromosomes
    Definitions
    TestTriple Screen
    Test typeMaternal serum screen
    AnalytesAlpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and estriol

    Covered Indications

    Aneuploidy Screening in Singleton or Twin Pregnancies

    Covered when all of the following requirements are met.

    Covered indication

    • The pregnancy is a singleton or twin pregnancy.>10 weeks gestation
    • Screening is for fetal trisomy 13, trisomy 18, and trisomy 21.
    • Coverage applies regardless of maternal age or risk of chromosomal abnormality.

    Fetal RhD Genotyping Using cfDNA

    Medically necessary when all of the following requirements are met.

    Fetal RhD genotyping

    Eligibility Requirements

    Eligibility requires that no chromosomal abnormality screening test has been performed in the current pregnancy. This includes sequential serum screening, quadruple screening, penta screening, and serum integrated or contingent screening. Only one aneuploidy screening approach may be used for the pregnancy.

    Not Covered Services

    The following services are not covered or are considered experimental, investigational, or unproven: higher-order multiple gestations, including triplets and higher; twin zygosity; rare autosomal trisomies such as trisomy 7, 9, 16, and 22; microdeletion screening; single-gene disorder testing; testing for the genetic cause of miscarriage; screening for nonmedical traits; the Luna Prenatal Test; non-RhD fetal antigen testing; and the listed fetal RhD PCR, single-gene, microdeletion, and products-of-conception sequencing services.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyGenetic Testing for Non-Invasive Prenatal Testing (NIPT)
    Policy CodePolicy 20.15
    Change TypeModified
    Effective DateN/A
    Last ReviewMar 25, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for applicable NIPT services, except codes 81420, 81507, and 0327U.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Service CodesProvider Actions and AuthorizationPolicy BackgroundDefinitionsCovered IndicationsEligibility RequirementsNot Covered Services
  1. Only one aneuploidy screening approach is used for the pregnancy; concurrent analyte screening and cell-free DNA screening are not medically necessary.
  2. Testing used to determine a genetic cause of miscarriage, including missed abortion or incomplete abortion.
  3. Screening for nonmedical traits, such as biologic sex.
  4. Luna Prenatal Test, including code 0341U.
  5. Cell-free DNA testing for non-RhD red blood cell antigens, including code 0488U.
  6. Fetal RhD testing with code 0536U.
  7. Any other NIPT indication not specifically described as medically necessary under this policy.
  8. Rolling 12-month period
    Repeat testingDocumentation must establish that a repeated test is for a new pregnancy
    Sequencing-Based NIPT
    Gestational-age thresholdAt least 10 weeks of gestation
    Eligible pregnancyViable single or twin gestation
    Screened conditionsFetal trisomy 13, 18, and 21
    Prior Authorization

    81403 ALOB Authorization

    The prior authorization requirement for molecular code 81403 remains in effect for ALOB because its prior authorization approval rating is below 95%.

    • Code 81403: continue prior authorization for ALOB.
    Prior Authorization

    Pending 0494U Authorization Configuration

    Configuration of code 0494U for ALOB prior authorization is still pending. The code represents cfDNA-based testing for fetal Rh-D alone; the authorization request was made on 11/19/2025.

    • 0494U: Natera cfDNA-based fetal Rh-D-alone assay.
    • 0494U ALOB prior authorization configuration requested 11/19/2025 and remains pending.
    • Do not confuse 0494U with 0488U, which evaluates multiple non-Rh-D red blood cell antigens and is investigational and experimental.
    Documentation Required

    Required Clinical Documentation

    Before ordering NIPT, document the pregnancy and ordering-provider requirements, the member’s ability to provide informed consent, and required genetic counseling. Coverage applies to a singleton or twin pregnancy greater than 10 weeks, regardless of maternal age or risk of chromosomal abnormality.

    • Document singleton or twin pregnancy and gestational age greater than 10 weeks.
    • The test must be ordered by a provider who regularly manages pregnancy.
    • Document that the individual has capacity to make fully informed decisions and consent to treatment.
    • Document genetic counseling by a certified genetic counselor or qualified healthcare professional.
    Documentation Required

    Prior Screening Documentation

    Document whether prior chromosomal-abnormality or aneuploidy screening was performed in the current pregnancy. Only one aneuploidy screening approach should be used; serum analyte screening and cell-free DNA screening should not be sent concurrently.

    • Document absence or presence of prior sequential serum Part 1 screening (81508), sequential serum Part 2 or quadruple screening (81511), penta screening (81512), and serum integrated or contingent screening.
    • If a screen-positive serum analyte result exists, cfDNA screening as follow-up may be reviewed case by case for individuals seeking to avoid diagnostic testing.
    • If aneuploidy screening with 81420 or 81507 has already been performed, additional chromosomal-abnormality screening for the same pregnancy is generally not medically necessary.
    Documentation Required

    Supporting Documentation

    When Presbyterian applies an external guideline, providers are expected to maintain or have access to documentation supporting coverage and medical necessity for review when requested.

    • Maintain supporting documentation for coverage determinations based on MCG, LCDs, NCDs, NCCN, or another external guideline.
    • Additional information supporting medical necessity may be submitted when the member does not meet the stated criteria.
    Denial Risk

    Situations Likely to Result in Denial

    Claims are likely to be denied when the clinical, utilization, or indication requirements are not met. Confirm eligibility and documentation before ordering or submitting the claim.

    • Gestational age is not greater than 10 weeks.
    • Pregnancy is a higher-order multiple gestation, such as triplets or higher.
    • More than two NIPT tests are billed in a rolling 12-month period without documentation that the testing is for a new pregnancy.
    • A prior chromosomal-abnormality screening test was performed in the same pregnancy, or serum analyte and cfDNA screening are ordered concurrently without an applicable case-by-case review.
    • The test is ordered by a provider who does not regularly manage pregnancy, required genetic counseling or informed-consent documentation is absent, or the member does not meet applicable coverage criteria.
    • The indication is excluded as experimental, investigational, or unproven.
    Denial Risk

    Investigational and Experimental Testing

    Claims for listed non-covered indications and services are at risk of denial because Presbyterian considers them experimental, investigational, or unproven.

    • Twin zygosity, including code 0060U.
    • Screening for trisomy 7, 9, 16, 22, or other rare autosomal trisomies.
    • Screening for microdeletions, including code 81422.
    • Single-gene-disorder testing, including UNITY Fetal Risk code 0489U.
    • Testing to determine the genetic cause of miscarriage.
    • Screening for nonmedical traits, such as biologic sex.
    • Luna Prenatal Test, including code 0341U.
    • Testing for non-Rh-D red blood cell antigens, including code 0488U.
    • Code 0536U, an RhD assay limited to a single exon of the RHD gene.
    • The listed codes are configured or designated as investigational and experimental/non-covered as applicable.
    Denial Risk

    Higher-Order Multiple Gestations

    NIPT for higher-order multiple gestations is excluded and considered experimental, investigational, or unproven. Coverage criteria apply to viable singleton and twin pregnancies, not triplets or higher-order multiples.

    • Triplets and higher-order multiple gestations are excluded under the policy.
    • Do not assume coverage for NIPT based solely on gestational age when the pregnancy is higher order.
    Documentation Required

    Complete Genetic Counseling Before NIPT

    Before ordering NIPT, ensure the member receives appropriate pre-test genetic counseling and can make a fully informed decision about testing and consent. Counseling must be provided by a certified genetic counselor or qualified healthcare professional.

    • Complete and document pre-test genetic counseling.
    • Document informed decision-making and consent capacity.
    Billing Rule

    Order NIPT Within Pregnancy Management

    NIPT may be ordered only by a provider who regularly manages pregnancy. Document the ordering provider’s role and the pregnancy-management relationship in the clinical record.

    • Ordering provider must regularly manage pregnancy.
    • This requirement applies in addition to gestational-age, pregnancy-type, counseling, screening, and authorization requirements.
    Definitions
    TestQuadruple Screen
    Test typeMaternal serum screen
    AnalytesAlpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), estriol, and inhibin A
    Definitions
    TestPenta Screen
    Test typeMaternal serum screen
    AnalytesAFP, unconjugated estriol (uE3), total hCG, hyperglycosylated hCG, and DIA
    Definitions
    TestSequencing-based non-invasive prenatal testing
    PurposeScreens for fetal trisomy 13, 18, and 21
    Applicable pregnancyViable single or twin gestation at 10 or more weeks of gestation
    Definitions
    TestUNITY Fetal Antigen
    MethodAnalysis of one or more fetal red blood cell antigens
    Antigen scopeRh, C, c, D, E, Duffy (Fya), or Kell (K) antigens
    • Fetal RhD genotyping is performed using cell-free DNA.
    • All criteria in MCG A-0724, Noninvasive Prenatal Testing (Cell-Free Fetal DNA), are met.

    Sequencing-Based NIPT for Trisomies 13, 18, and 21

    Medically necessary when all of the following requirements are met.

    Sequencing-based NIPT

    • The gestation is viable and is either single or twin.Gestational age ≥10 weeks
    • Screening is for fetal trisomy 13, trisomy 18, and trisomy 21.

    Maternal Serum Screening

    Covered as standard prenatal maternal serum screening when the applicable benefit requirements are met.

    Maternal serum screening

    • The service is one of the standard prenatal screening tests represented by codes 81508, 81509, 81510, 81511, or 81512.
    • The applicable prior-authorization requirement has been removed for ALOB.

    cfDNA-Based Testing for Rh-D Alone

    Covered when the applicable medical-necessity requirements are met.

    cfDNA-based Rh-D testing

    • Testing is cfDNA-based testing for Rh-D alone, represented by code 0494U.
    • The testing follows the applicable MCG A-0724 criteria.

      Prior-authorization configuration for ALOB was requested and remains pending.